The most clinically validated peptide for weight management. FDA-approved as both Ozempic (diabetes) and Wegovy (weight loss), with the oral formulation launching in early 2026.
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. It slows gastric emptying, reduces appetite via hypothalamic signaling, improves insulin sensitivity, and promotes satiety. The result is reduced caloric intake and improved metabolic parameters including HbA1c, fasting glucose, and lipid profiles.
Women with PCOS (1 in 10) frequently experience insulin resistance-driven weight gain that is resistant to conventional diet and exercise. Semaglutide directly addresses insulin signaling pathways. For menopausal women, the metabolic shift caused by declining estrogen makes weight management increasingly difficult — GLP-1 agonists provide pharmacological support for this transition.
Common side effects include nausea (especially during dose titration), vomiting, diarrhea, constipation, and abdominal pain. These typically improve over time. Serious but rare risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumor risk (boxed warning based on animal studies).
This peptide is part of our Weight Management hub — explore all peptides for this use case.
Semaglutide improves insulin sensitivity and promotes weight loss, both of which directly benefit women with PCOS. While not FDA-approved specifically for PCOS, GLP-1 agonists are increasingly used off-label for PCOS-related metabolic dysfunction. Discuss with your endocrinologist.
Yes — the oral formulation of semaglutide (Rybelsus for diabetes, and the Wegovy pill for weight loss launched in early 2026) is now available. Oral dosing requires taking it on an empty stomach with minimal water.
Phase III STEP trials showed average weight loss of 15-17% of body weight over 68 weeks. Individual results vary based on starting weight, diet, exercise, and adherence. Weight regain after discontinuation is common without lifestyle changes.
Medical Disclaimer: This profile is for educational purposes only. It is not medical advice, a treatment recommendation, or a prescription guide. Always consult a licensed healthcare provider before starting any peptide therapy. Evidence ratings reflect the current state of published research and may change as new data emerges.
Affiliate Disclosure: Vendor links above are affiliate partnerships. FemPeptides may earn a commission on purchases. This does not influence our editorial content or evidence ratings. Full disclosure →
Take our 60-second quiz for a personalized recommendation based on your goals and life stage.
Find Your Peptide →